Kite Pharma Inc (NASDAQ:KITE) announced results from SCHOLAR-1 (Retrospective Non-Hodgkin Lymphoma Research), the first, large, systematic, multi-institutional, patient-level meta-analysis of outcomes from 635 patients …
Kite Pharma Inc (NASDAQ:KITE) announced that it has entered into a clinical trial collaboration with Genentech, a member of the Roche Group, to evaluate …
Kite Pharma Inc (NASDAQ:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy (eACT™) products for the treatment of cancer, today provided …
The biotech sector is taking center stage this week as several key players are scheduled to announced earnings. Investors and analysts are looking …
Kite Pharma Inc (NASDAQ:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy (eACT™) products for the treatment of cancer, today announced …
Following the annual J.P.
Kite Pharma, Inc. (NASDAQ:KITE) announced that its European subsidiary has entered into a research and license agreement with Leiden University Medical Center (LUMC) to …
Kite Pharma, Inc. (NASDAQ:KITE) announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the NCI for the research and …
Kite Pharma Inc (NASDAQ:KITE) announced that it has appointed Shawn Tomasello to the newly created position of Chief Commercial Officer. With over 30 …
Kite Pharma Inc (NASDAQ:KITE) announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an …
